Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 1,198 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 1,198 shares of the company’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total transaction of $510,755.32. Following the completion of the transaction, the chief financial officer directly owned 49,658 shares in the company, valued at $21,171,191.72. The trade was a 2.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The stock was sold at an average price of $425.55, for a total transaction of $811,098.30.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The shares were sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Stock Performance

Shares of NTRA stock opened at $414.30 on Friday. The firm’s 50 day moving average price is $377.06 and its 200-day moving average price is $266.44. Natera, Inc. has a one year low of $181.00 and a one year high of $437.41.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same quarter last year, the company posted ($0.74) EPS. The firm’s quarterly revenue was up 37.7% on a year-over-year basis. On average, research analysts forecast that Natera, Inc. will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On Natera

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Natera in the second quarter valued at $2,962,770,000. Bank of America Corp DE purchased a new position in Natera in the second quarter valued at $199,960,000. Legal & General Group Plc purchased a new position in Natera in the second quarter valued at $150,143,000. Bank of New York Mellon Corp purchased a new position in Natera in the second quarter valued at $149,278,000. Finally, Avala Global LP acquired a new position in Natera during the 2nd quarter worth $124,867,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on NTRA shares. BTIG Research upped their price target on Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their price objective on Natera from $360.00 to $460.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Stephens boosted their price objective on Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, August 12th. Wells Fargo & Company boosted their price objective on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Finally, Royal Bank Of Canada increased their target price on Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a research note on Friday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $394.31.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.